Helix BioMedix (HXBM) Ratios

4 Followers

Helix BioMedix Ratios

See a summary of HXBM’s cash flow.

Ratios	Dec 25	Dec 23	Dec 22	Dec 21
Liquidity Ratios
Current Ratio	―	12.16	44.99	30.24	55.34
Quick Ratio	―	12.16	44.99	30.24	55.29
Cash Ratio	―	9.20	38.40	27.20	33.73
Solvency Ratio	―	-3.97	-15.63	-9.34	-12.52
Operating Cash Flow Ratio	―	-4.37	-13.00	-5.76	-9.90
Short-Term Operating Cash Flow Coverage	―	0.00	0.00	-10.22	0.00
Net Current Asset Value	$ ―	$ 1.54M	$ 2.94M	$ 3.69M	$ 4.67M
Leverage Ratios
Debt-to-Assets Ratio	―	0.00	0.00	0.02	0.00
Debt-to-Equity Ratio	―	0.00	0.00	0.02	0.00
Debt-to-Capital Ratio	―	0.00	0.00	0.02	0.00
Long-Term Debt-to-Capital Ratio	―	0.00	0.00	0.00	0.00
Financial Leverage Ratio	―	1.09	1.02	1.03	1.02
Debt Service Coverage Ratio	―	0.00	0.00	-16.57	-2.83
Interest Coverage Ratio	―	0.00	0.00	0.00	-3.76
Debt to Market Cap	―	0.00	0.00	0.01	0.00
Interest Debt Per Share	―	0.00	0.00	0.32	1.56
Net Debt to EBITDA	―	2.32	2.46	2.85	2.93
Profitability Margins
Gross Profit Margin	―	99.36%	99.02%	99.11%	81.30%
EBIT Margin	―	-68.32%	-105.85%	-67.94%	-42.50%
EBITDA Margin	―	-67.68%	-104.87%	-67.22%	-41.94%
Operating Profit Margin	―	-73.81%	-98.63%	-61.48%	-55.75%
Pretax Profit Margin	―	-68.32%	-105.85%	-67.94%	-57.32%
Net Profit Margin	―	-68.32%	-105.85%	-67.94%	-57.32%
Continuous Operations Profit Margin	―	-68.32%	-105.85%	-67.94%	-57.32%
Net Income Per EBT	―	100.00%	100.00%	100.00%	100.00%
EBT Per EBIT	―	92.56%	107.32%	110.51%	102.80%
Return on Assets (ROA)	―	-32.90%	-34.91%	-30.33%	-28.12%
Return on Equity (ROE)	―	-35.84%	-35.70%	-31.34%	-28.76%
Return on Capital Employed (ROCE)	―	-38.72%	-33.27%	-28.36%	-27.85%
Return on Invested Capital (ROIC)	―	-38.72%	-33.27%	-27.84%	-27.85%
Return on Tangible Assets	―	-32.90%	-34.91%	-30.33%	-28.12%
Earnings Yield	―	-122.72%	-20.20%	-22.77%	-50.45%
Efficiency Ratios
Receivables Turnover	―	2.56	3.19	6.84	5.09
Payables Turnover	―	0.42	0.22	3.68	18.75
Inventory Turnover	―	0.00	0.00	0.00	120.49
Fixed Asset Turnover	―	2.45K	83.44	17.55	61.77
Asset Turnover	―	0.48	0.33	0.45	0.49
Working Capital Turnover Ratio	―	0.45	0.30	0.42	0.68
Cash Conversion Cycle	―	-722.32	-1.53K	-45.72	55.25
Days of Sales Outstanding	―	142.69	114.47	53.36	71.68
Days of Inventory Outstanding	―	0.00	0.00	0.00	3.03
Days of Payables Outstanding	―	865.01	1.64K	99.08	19.47
Operating Cycle	―	142.69	114.47	53.36	74.71
Cash Flow Ratios
Operating Cash Flow Per Share	―	-2.67	-3.87	-3.24	-3.80
Free Cash Flow Per Share	―	-2.67	-3.88	-3.24	-3.84
CapEx Per Share	―	<0.01	<0.01	<0.01	0.03
Free Cash Flow to Operating Cash Flow	―	1.00	1.00	1.00	1.01
Dividend Paid and CapEx Coverage Ratio	―	-200.36K	-660.25	-541.06	-112.49
Capital Expenditure Coverage Ratio	―	-200.36K	-660.25	-541.06	-112.49
Operating Cash Flow Coverage Ratio	―	0.00	0.00	-10.22	0.00
Operating Cash Flow to Sales Ratio	―	-0.74	-0.87	-0.41	-0.36
Free Cash Flow Yield	―	-133.75%	-16.67%	-13.93%	-31.98%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	―	-0.82	-4.95	-4.39	-1.98
Price-to-Sales (P/S) Ratio	―	0.56	5.24	2.98	1.14
Price-to-Book (P/B) Ratio	―	0.29	1.77	1.38	0.57
Price-to-Free Cash Flow (P/FCF) Ratio	―	-0.75	-6.00	-7.18	-3.13
Price-to-Operating Cash Flow Ratio	―	-0.75	-6.01	-7.19	-3.16
Price-to-Earnings Growth (PEG) Ratio	―	0.02	0.43	0.36	0.06
Enterprise Value Multiple	―	1.50	-2.54	-1.59	0.22
Enterprise Value	―	-817.09K	2.66M	1.87M	-216.75K
EV to EBITDA	―	1.50	-2.54	-1.59	0.22
EV to Sales	―	-1.01	2.66	1.07	-0.09
EV to Free Cash Flow	―	1.36	-3.05	-2.57	0.25
EV to Operating Cash Flow	―	1.36	-3.06	-2.57	0.25
Tangible Book Value Per Share	―	6.85	13.16	16.93	21.05
Shareholders’ Equity Per Share	―	6.85	13.16	16.93	21.05
Tax and Other Ratios
Effective Tax Rate	―	0.00	0.00	0.00	0.00
Revenue Per Share	―	3.59	4.44	7.81	10.56
Net Income Per Share	―	-2.45	-4.70	-5.31	-6.05
Tax Burden	―	1.00	1.00	1.00	1.00
Interest Burden	―	1.00	1.00	1.00	1.35
Research & Development to Revenue	―	0.22	0.32	0.51	0.52
SG&A to Revenue	―	1.51	0.00	0.00	0.00
Stock-Based Compensation to Revenue	―	0.00	0.00	0.00	0.00
Income Quality	―	1.09	0.82	0.61	0.63

Currency in USD